Branded generics business drives earnings growth

Company
27 May 2024
5 Min read 
  • Torrent Pharma's 4QFY24 results show neutral rating with a TP change.
  •  Branded generics business drives earnings growth for Torrent Pharma.
  •  Financials and valuations for FY24, FY25E, and FY26E are provided.
  •  The company delivered in-line operational performance for 4QFY24.
  •  Shareholding pattern, sales growth, and financial highlights are detailed.
  •  Key takeaways from the management interaction and focused efforts in different segments.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority